Fusion Genes Predict Prostate Cancer Recurrence

Abstract

This Impact Award between the University of Pittsburgh, Stanford University and University of Wisconsin at Madison seeks to provide definitive clinical validation of low copy number transcript fusions as prognostic markers in clinically localized prostate cancer. The Stanford site is charged with providing formalin fixed paraffin embedded samples for independent validation of markers discovered at University of Pittsburgh. To that end, we have shipped 300 samples for assay testing and have accumulated over 600 FFPE blocks of radical prostatectomy specimens with detailed clinical follow-up. The assay results suggest that there are some artifacts, and University of Pittsburgh will be addressing these issues. Next year we will increase the number of samples accumulated to get to our goals. We will be sending specimens blinded to the Pittsburgh site and include controls for assay performance. We have agreed to allow the Stanford and Wisconsin sites to receive data from Pittsburgh to perform correlation with clinical data and correlation with outcomes at these sites.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2017
Accession Number
AD1047903

Entities

People

  • David F Jarrard

Organizations

  • University of Wisconsin–Madison

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biomedical Research
  • Institutional Review Board
  • Local Governments
  • Management Personnel
  • Medical Personnel
  • Neoplasms
  • Patent Applications
  • Personnel Management
  • Professional Development
  • Prostate
  • Prostate Cancer
  • Quality Control
  • Standards
  • Students
  • Tissues
  • Validation
  • Wisconsin

Readers

  • Oncology and Biomarker-Based Cancer Detection.